Non-muscle invasive bladder cancer (NMIBC) is a common form of bladder cancer that has not yet spread beyond the inner layer of the bladder. NMIBC accounts for around 75% of new cases of bladder cancer diagnosed each year in the United States. The exact causes of NMIBC are still unknown, however certain risk factors such as smoking, exposure to chemicals in the workplace, and genetic factors may increase the likelihood of developing this type of bladder cancer.
Symptoms And Diagnosis Of NMIBC
The main symptoms of Non-Muscle Invasive Bladder Cancer include blood or blood clots in the urine, frequent urges to urinate, and painful urination. However, these symptoms can also be caused by other non-cancerous health conditions as well. A doctor will usually recommend cystoscopy and urine testing to help diagnose NMIBC. During cystoscopy, a thin camera is inserted through the urethra to examine the inner surface of the bladder. Abnormal tissues detected during cystoscopy are then removed for biopsy to check for cancerous cells under a microscope. Urine tests can also detect traces of blood or tumor cells in the urine which may indicate the presence of bladder cancer.
Stages And Grading Of Non-Muscle Invasive Bladder Cancer
NMIBC is divided into three stages - stage 0, stage Ta, and stage T1. Stage 0 refers to carcinoma in situ (CIS), where the cancer is found only in the inner layer of the bladder cells and has not grown into deeper layers. Stage Ta means the cancer has grown into the inner layer but not into deeper layers of the bladder. Stage T1 is when the cancer has grown into the connective tissue just beneath the inner lining of the bladder but has not spread outside the bladder.
In addition to staging, NMIBC tumors are also assigned a grade from G1 to G3 based on how aggressive they look under the microscope. Low-grade (G1) tumors usually grow slowly while high-grade (G3) tumors tend to grow and spread more quickly. Accurately staging and grading NMIBC helps doctors determine the appropriate treatment approach and predict the likelihood of recurrence.
Treatment Options For NMIBC
Treatment for NMIBC depends on the stage and grade of the cancer. For stage 0 or Ta G1 grade tumors, the standard first-line treatment is transurethral resection of the bladder tumor (TURBT). During this procedure, any visible tumors are surgically removed but the bladder lining and muscle layer remain intact. For higher risk stage Ta or T1 tumors, doctors may recommend additional treatment with intravesical therapy immediately after TURBT.
Intravesical therapy involves administering chemotherapy or immunotherapy medications directly into the bladder using a catheter. The most common intravesical medications are Bacillus Calmette-Guerin (BCG) immunotherapy and Mitomycin C chemotherapy. BCG treatment has the benefit of reducing recurrence rates more than chemotherapy alone in high-grade NMIBC. For recurrent or residual tumors after initial treatment, further TURBT or more aggressive therapies may be needed. In rare cases where the cancer recurs as muscle-invasive disease, radical cystectomy (complete bladder removal) may become necessary.
Rising Incidence And Healthcare Burden
Statistics show the incidence and prevalence rates of Non-Muscle Invasive Bladder Cancer have been rising over the past few decades. This increased occurrence corresponds to aging populations and growing risk factors like smoking in many Western countries. The National Cancer Institute estimates around 80,470 new cases of bladder cancer will be diagnosed in the United States in 2022 alone. Managing NMIBC poses a considerable economic burden on the healthcare system as well. The costs of long-term surveillance and recurrent treatment make bladder cancer one of the most expensive cancers to manage over a patient's lifetime. Experts project costs associated with NMIBC will continue escalating unless steps are taken to curb risk factors and improve outcomes through new treatment innovations.
Bladder Preservation As An Alternative To Cystectomy
For select high-risk NMIBC cases where cystectomy may otherwise be recommended, bladder preservation approaches are being explored as a potentially better alternative. Using maximal transurethral resection combined with multidrug intravesical chemo-immunotherapy and close monitoring, some studies show it is possible to preserve the bladder in over 70-80% of such patients, avoiding the morbidities of bladder removal surgery. However, patient selection criteria and long-term oncologic outcomes still need validation through larger randomized trials before bladder preservation can become a standard option. Ongoing research into new targeted drugs, immunotherapies, and molecular biomarkers may also help improve risk stratification and personalize bladder preservation approaches in the future.
Outlook
Non-Muscle Invasive Bladder Cancer accounts for the majority of new bladder cancer cases seen annually. Although less aggressive than muscle-invasive disease, NMIBC poses growing socio-economic and healthcare challenges due to high recurrence rates requiring life-time surveillance. Current management relies on transurethral resection combined with intravesical chemo-immunotherapies, with cystectomy reserved for refractory cases. Bladder preservation is being explored as an alternative to radical cystectomy in selected high-risk patients. Going forward, better prevention, accurate risk stratification aided by biomarkers, newer drugs, and personalized treatment protocols hold promise to reduce morbidity and costs related to NMIBC in the coming years.
Get more insights on this topic: https://www.trendingwebwire.com/non-muscle-invasive-bladder-cancer-symptoms-stages-and-treatment-options/
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Comments
0 comment